<code id='5A5D93C4CA'></code><style id='5A5D93C4CA'></style>
    • <acronym id='5A5D93C4CA'></acronym>
      <center id='5A5D93C4CA'><center id='5A5D93C4CA'><tfoot id='5A5D93C4CA'></tfoot></center><abbr id='5A5D93C4CA'><dir id='5A5D93C4CA'><tfoot id='5A5D93C4CA'></tfoot><noframes id='5A5D93C4CA'>

    • <optgroup id='5A5D93C4CA'><strike id='5A5D93C4CA'><sup id='5A5D93C4CA'></sup></strike><code id='5A5D93C4CA'></code></optgroup>
        1. <b id='5A5D93C4CA'><label id='5A5D93C4CA'><select id='5A5D93C4CA'><dt id='5A5D93C4CA'><span id='5A5D93C4CA'></span></dt></select></label></b><u id='5A5D93C4CA'></u>
          <i id='5A5D93C4CA'><strike id='5A5D93C4CA'><tt id='5A5D93C4CA'><pre id='5A5D93C4CA'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:73
          Alastair Grant/AP

          Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

          So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system. 

          advertisement

          The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more
          It shouldn't be easy to buy synthetic DNA to recreate a deadly virus
          It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

          AdobeItshouldbehard—exceedinglyhard—toobtainthesyntheticDNAneededtorecreatethevirusthatcausedthedead

          read more
          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more

          The story of mRNA: From a loose idea to a tool that may help curb Covid

          Partofa"freezerfarm,"afootballfield-sizedfacilityforstoringfinishedCovid-19vaccines,underconstructio